|Bid||0.0000 x 1400|
|Ask||0.0000 x 1800|
|Day's Range||2.4700 - 2.6332|
|52 Week Range||2.4700 - 12.3550|
|Beta (3Y Monthly)||0.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
BOSTON, April 04, 2019 -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology.
NEW YORK , April 2, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with Amyris' announcement that it was unable ...
BENSALEM, Pa., March 30, 2019 -- Law Offices of Howard G. Smith announces an investigation on behalf of Zafgen, Inc. investors (“Zafgen” or the “Company”) (NASDAQ: ZFGN).
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Zafgen, Inc. (“Zafgen” or the “Company”) (NASDAQ: ZFGN) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. On March 11, 2019, Zafgen announced its decision to suspend plans to file an investigational new drug application for ZGN-1258, the Company’s candidate for rare metabolic disorders based on a finding in rodent toxicology studies.
The most recent earnings announcement Zafgen, Inc.'s (NASDAQ:ZFGN) released in December 2018 signalled company earnings became less negative compared to the previous year's level - great news for investors Below,Read More...
BOSTON, March 13, 2019 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 11) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
Zafgen is shelving plans to begin testing another drug, ZGN-1258, after new preclinical data linked it to muscle degeneration and other abnormalities.
The Boston-based company said it had a loss of 39 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss ...
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for ZGN-1061 Suspends IND.
BOSTON, March 07, 2019 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel.
BOSTON, March 06, 2019 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel.
Zafgen, Inc. (ZFGN) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced the appointment of Priya Singhal, M.D., M.P.H., as Head of Research and Development. Dr. Singhal brings more than a decade of experience as a senior drug development executive and several years of experience as a clinician to her role at Zafgen, where she will lead and oversee the Company’s research, clinical and manufacturing strategy and implementation. Dr. Singhal joins Zafgen most recently from Biogen, where she was concurrently the Senior Vice President and the Global Head of Safety and Benefit Risk Management (SABR) and the Interim Global Co-lead and Senior Vice President of Global Development.
The announcement of what appeared to be positive mid-stage trial data seemed to do little to assuage investors in light of the fact that the drug remains on hold due to cardiovascular concerns.
Zafgen, Inc. (ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced positive data for the second cohort of its Phase 2 clinical trial of ZGN-1061, designed to evaluate efficacy and safety in patients with type 2 diabetes and the likely therapeutic dose range of ZGN-1061 up to 1.8 mg. The clinical trial met all of its primary objectives at the 1.8 mg dose, which included glycemic control, or change in A1C, and safety and tolerability. The 12-week data demonstrated that treatment with the 1.8 mg dose of ZGN-1061 produced substantially more improvement in A1C than the 0.9 mg dose.
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]
David Kim’s Ghost Tree Capital is a health-care oriented hedge fund with a headquarter in New York. It was founded five years ago, back in 2013, by Ken Greenberg, Matt Diaz (Trader), Brian Kim (Senior Analysts), and of course David Kim. This large advisory firm provides portfolio management services for pooled investment vehicles and pension funds. David […]
Zamansky LLC announces that it is investigating Zafgen, Inc. (ZFGN) (“Zafgen” or the “Company”) for potential breaches of fiduciary duties by its officers and board of directors. If you are a shareholder of Zafgen who still holds your shares, please contact our firm for information. It has recently emerged from public filings that Zafgen has received a letter from the U.S. Food and Drug Administration (“FDA”) citing possible cardiovascular safety risks associated with the clinical trial of a new type 2 diabetes drug ZGN-1061 as the reason for placing a clinical hold on the trial.
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zafgen, Inc. (''Zafgen'' or the ''Company'') (NASDAQ: ZFGN). ...
Pomerantz LLP is investigating claims on behalf of investors of Zafgen, Inc. (“Zafgen” or the “Company”) (NASDAQ: ZFGN). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. On November 26, 2018, Zafgen announced receipt of a letter from the U.S. Food and Drug Administration (“FDA”) placing a clinical hold on the Investigational New Drug Application for its first U.S. clinical trial of ZGN-1061, the Company’s second-generation, investigational MetAP2 inhibitor currently in development for the treatment of type 2 diabetes.